Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment

Hao Wang; Sha Zhao; Xiaoshen Zhang; Keyi Jia; Juan Deng; Caicun Zhou; Yayi He

doi:10.2147/OTT.S214231

Major histocompatibility complex class II molecule in non-small cell lung cancer diagnosis, prognosis and treatment

Onco Targets Ther. 2019 Sep 5:12:7281-7288. doi: 10.2147/OTT.S214231. eCollection 2019.

Authors

Hao Wang^{1

2}, Sha Zhao^{1

2}, Xiaoshen Zhang^{1

2}, Keyi Jia^{1

2}, Juan Deng^{1

2}, Caicun Zhou¹, Yayi He¹

Affiliations

¹ Department of Medical Oncology, Shanghai Pulmonary Hospital, Tongji University Medical School Cancer Institute, Tongji University School of Medicine, Shanghai 200433, People's Republic of China.
² Medical School, Tongji University, Shanghai 200433, People's Republic of China.

Abstract

Lung cancer is one of the commonest cancers in the world. More than 70% of lung cancer patients are diagnosed with non-small cell lung cancer (NSCLC). Major histocompatibility complex class II (MHC class II), an important component in antigen presenting process, usually expresses on professional antigen presenting cells (APCs), and it can be induced by interferon-γ (IFN-γ). MHC class II can be expressed by NSCLC cells. In NSCLC patients, the expression of MHC class II can be correlated with the outcome of anti-programmed death-1 (anti-PD-1) therapy. This review summarizes MHC class II expression in NSCLC and the correlation between MHC class II and NSCLC diagnosis, prognosis and therapy.

Keywords: immune therapy; major histocompatibility complex class II; non-small cell lung cancer.